peptide and peptidomimetic drugs b

Conformational Flexibility

Peptides and proteins exhibit high rotational freedom due to single bonds in their backbone, creating multiple equilibrium conformations.

Structural Dependence

Refers to how the primary and secondary structure of peptides determine reactivity and biological activity.

Proteolytic Metabolism

The process where peptides are degraded by proteases, particularly at the N- and C-termini.

Half-Life

The duration that a peptide remains active in the body, often short for naturally occurring peptides like oxytocin.

Peptidomimetics

Synthetic molecules designed to mimic the structure and function of peptides while improving their stability, activity, and delivery.

D-Amino Acids

Amino acids that are not commonly found in natural proteins, used in modifications to prevent protease recognition.

Terminal Modifications

Chemical alterations at the peptide ends to enhance stability, such as acetylation at the N-terminus.

Cyclization

A structural modification that enhances rigidity and reduces degradation by restricting protease access.

Oxytocin

A peptide hormone that promotes uterine contractions; its synthetic analogs may have extended half-lives for therapeutic use.

GnRH

Gonadotropin-Releasing Hormone, which regulates the release of LH and FSH, and induces ovulation.

Super-Agonist Design

Strategies like D-amino acid substitutions and cyclization used to enhance the potency and half-life of peptide analogs.

Somatostatin

A hormone that inhibits growth hormone secretion and contains a disulfide bridge that stabilizes its active structure.

Integrin Antagonists

Molecules that block integrin receptors, which are important for cell adhesion and signal transduction.

GLP-1

Glucagon-like peptide-1, an incretin hormone that stimulates insulin secretion and is rapidly degraded by DPP-4.

Radiolabeled Peptides

Peptide-based drugs that are combined with radionuclides for use in cancer imaging or therapy.

Eptifibatide

A cyclic peptide that serves as an integrin antagonist, preventing platelet aggregation.

Cilengitide

A peptidomimetic targeting αvβ3 integrins, evaluated for its anti-cancer effects in glioblastoma trials.

Exenatide

A synthetic analogue of GLP-1 derived from Gila monster saliva, used for type 2 diabetes.

Semaglutide

A long-acting GLP-1 analogue designed for weekly dosing through acylation with a fatty acid.